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Methods: 78 chronic hepatitis B patients who were
given telbivudine 600mg daily were divided in different
groups according to the sex, age, HBeAg seroconversion,
biochemical response and virological response. The rate and
average of CK elevation were analyzed in these groups.
Results: CK elevation was observed in 61.54% patients
(48/78), 69.12% in male (47/68), 10% in female (1/10),
46.15% in seroconversion group (6/13), 60.98% in SVR group
(25/41). High CK elevation (3 times higher then average)
was observed in 4 patients with kinetic intensity during the
treatment.
Conclusion: Sex and seroconversion are the factors related
to CK elevation during telbivudine treatment and the kinetic
intensity is related to high CK elevation level.
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Objective: To lay a foundation for the further development
of a novel vaccine based on TGF-b1, a pivotal cytokine,
leading to hepatic ﬁbrosis, we detected the neutralization
activity and evaluated anti-liver ﬁbrosis activity by keyhole
limpet hemocyanin (KLH) coupled TGF-b1 domain antigen
peptide vaccine.
Methods: Possible TGF-b1 domain B-cell epitope was
predicted by bioinformatics, then KLH-coupled peptide was
synthesized by the FMOC method. Hepatic injury model rats
were induced by CCl4 for 10 weeks. 40 male SD rats were
randomly divided into four groups: normal group (olive oil),
adjuvant group (freund’s adjuvant), vaccine group (50 mg
TGF-b1 peptide vaccine+CCl4), model group (CCl4). Serum
TGF-b1 antibody, HA, IV-C, ALT, AST, TBIL, ALB and GLB were
detected; Levels of Hydroxyproline in hepatic tissue were
measured and liver tissues were obtained for pathological
observation.
Results: A certain amount of serum antibody was induced by
TGF-b1 peptide vaccine in vaccine group, but no signiﬁcantly
different statistics were observed compared to other groups
(P> 0.05). The data showed high levels of ALT, TBIL, HA, IV-C
and Hyp in both of model and vaccine groups compared
with normal group respectively (P< 0.05). The ALT, AST and
TBIL levels in vaccine group were lower than model group
(P< 0.05), but HA, IV-C and Hyp content were no statistical
signiﬁcances (P> 0.05). HE and VG staining showed different
degree hepatic ﬁbrosis in model and vaccine groups.
Conclusions: TGF-b1 peptide vaccine cannot remarkably
stimulate antibody production, but the liver function of
vaccine group can be mitigated to some extent.
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Background: Based on the existing model of virus infection,
we bring up a new model which has logistic growth term and
loss of free virus term caused by virus’s entering uninfected
cells. In this presentation, we do an individual simulation
with the new model to test the consistency of clinical and
simulation data.
Methods: The patient has received a 96 weeks therapy of
Adefovir. The model was described with three variables:
x, y, v and 7 parameters: l, d, b, a, u, p, M, k where p, M
represent uninfected cells’ growth rate and environmental
carrying capacity respectively and the other symbols have
the same meaning as those in the basic Nowak model. We
chose {lambda, d, b, a, u, p, M, k} = {1.2067e+6, 0.0181,
0.1158, 0.0217, 0.1600, 0.0163, 6.6667e+012, 0.0140}.
Results: The clinical data and simulation result are
presented in Table 1.
Conclusion: The simulation data is relatively consistent
with clinical data which means our model can capture the
dynamic character of HBV virus to some extent.
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Table 1: HBV DNA (log copies/ml)
Virus load/weeks 0 12 24 36 48 60 72 84 96
Clinical data 1.27e8 7.78e4 2.28e4 2.28e4 1.84e4 1.22e4 7.73e2 250 250
Simulation data 1.27e8 6.74e5 1.83e5 4.97e4 1.35e4 3.68e3 1.00e3 273.03 74.32
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Background: Entecavir (ETV) is believed to reduce
covalently closed circular DNA. Leonieke et. al gave some
patients’ clinical data of 28 days’ therapy of ETV and the
data after withdraw of therapy. Leonieke et. al also simu-
lated the data by bi-phasic model, but the bi-phasic model
was only simpliﬁcation of Nowak’s basic model under some
conditions. Based on Leonieke et. al’s data and Nowak’s
model, we formulate a new dynamic model to simulate one
patient’s data during and after the ETV therapy.
Methods: A model of HBV is described by four variables: x,
y, v, e, representing uninfected cells, infected cells, free
virus, and immune cells. The model includes 10 parameters:
l, d, b, a, p, k, u, k2, k3, k4 where the meanings of l, d, b,
a, p, k, u are the same as those given in Nowak’s model, k2
represents the curative effect, k3, k4 are relevant to the
immune.
We chose the following parameters during treatment: {l, d,
b, a, p, u, k, k2, k3, k4, k5} = {4.621e5, 6.9e-3, 2.19e-11,
7.3e-3, 1.5e-4, 0.45, 2.37, 2.18, 3e-8, 3.65e-10, 0.1154}.
When the therapy was stopped, we chose {a, u, k2} =
{6.9e-3, 0.25, 0} in which k2 = 0 implies no therapy effect,
a, u becoming smaller means the die rate of infected cells
and free virus decrease after treatment.
Results: Our dynamic model can simulate the patient’s
clinical data during the course of treatment and the rebound
of HBV DNA after withdraw of therapy well.
Conclusion: The difference between the therapy and
withdraw of therapy can be embodied by our model, which
shows our model may possibly capture the dynamics of
anti-HBV infection treatment with ETV.
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Background: Entecavir (ETV) and Adefovir dipivoxil (AD)
are often used for HBV infection therapy. The use of
Mathematical models to interpret the experimental and
clinical data has made a signiﬁcant contribution to anti-HBV
infections. Based on Jurrien et al’s experimental data with
AD and ETV, considering the time delay of therapy effect
and antiviral drug resistance, we set up a mathematical
model with time delay to simulate the viral dynamics under
the therapy of ETV and AD.
